Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

CD47-blockade induces programmed necroptosis and complements the effects of BCL-2 inhibition in lymphoid malignancies

Blood (2025) 146 (Supplement 1): 1525.

https://doi.org/10.1182/blood-2025-1525

Published: 2025

Journal Articles

Epitranscriptomic signatures define prognosis and therapeutic vulnerabilities in large B-cell lymphoma

Caroline Molinaro, Jeanne Loiseau, Andrea Romero, Aurore Attina, Sonia Garcia Llorens, Alexandre David, Christophe Hirtz, Denis Coulomb, Guillaume Cartron, Ludovic Gabellier, Jerome Moreaux, Charles Herbaux

Blood (2025) 146 (Supplement 1): 5312.

https://doi.org/10.1182/blood-2025-5312

Published: 2025

Journal Articles

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Blood (2025) 146 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2025-5519

Published: 2025

Journal Articles

Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group

Blood (2025) 146 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2025-1019

Published: 2025

Journal Articles

Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy

Blood (2025) 146 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2025-1799

Published: 2025

Journal Articles

Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa

Blood (2025) 146 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2025-1797

Published: 2025

Journal Articles

Multi-omics integration reveals therapeutic vulnerabilities and immune microenvironment subtypes in Acute Myeloid Leukemia

Elina Alaterre, Hugues De Boussac, Alboukadel Kassambara, Alizee Steer, Amélie Machura, Julien Aityaya, Ouissem Karmous Gadacha, Matthieu Abouladzé, Caroline Bret, Gaspar Aspas Requena, Ludovic Gabellier, Charles Herbaux, Angélique Bruyer, Jerome Moreaux

Blood (2025) 146 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2025-1715

Published: 2025

Journal Articles

N6-methyladenosine (m6A) RNA modification is required to final plasma cell differentiation

Morgane Thomas, Elvira Garcia De Paco, Matthieu Angles, Caroline Bret, Nicolas Robert, Guilhem Requirand, Charles Herbaux, Aurore Attina, Christophe Hirtz, Giacomo Cavalli, Alexandre David, Jerome Moreaux

Blood (2025) 146 (Supplement 1): 5704.

https://doi.org/10.1182/blood-2025-5704

Published: 2025

Journal Articles

Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)

Tiy Morris, Amandine Fayard, Vivien Dupont, Elisabeth Daguenet, Catherine Thieblemont, Emmanuel Bachy, Guillaume Manson, Charles Herbaux, Ibrahim Yakoub-Agha, Thomas Gastinne, Didier Blaise, Louise Roulin, François-Xavier Gros, Pierre Bories, Roch Houot, Steven Le Gouill, Elisabeth Botelho-Nevers, Ludovic Fouillet, Jerome Cornillon

Blood (2025) 146 (Supplement 1): 1014.

https://doi.org/10.1182/blood-2025-1014

Published: 2025

Journal Articles

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2025-2745

Published: 2025

Journal Articles

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2025-2744

Published: 2025

Journal Articles

CRISPR-ko screen identifies RARα inhibition as a strategy to increase CD38 expression in multiple myeloma and potentiate anti-CD38 therapy.

Laura Alibert, Sara scaramuzzino, Camille Soun, Guilhem Requirand, Nicolas Robert, Laure Vincent, Charles Herbaux, Guillaume Cartron, Caroline Bret, Sandrine Roulland, Jerome Moreaux, Sara Ovejero

Blood (2025) 146 (Supplement 1): 2146.

https://doi.org/10.1182/blood-2025-2146

Published: 2025

Journal Articles

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3

Blood blood.2025029734.

https://doi.org/10.1182/blood.2025029734

Published: 2025

Includes: Supplemental data

Journal Articles

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Benoit Tessoulin, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Cedric Rossi, Caroline Milin, Ludovic Fouillet, Charles Herbaux, Emmanuelle Tchernonog, Rory McCulloch, Thomas Gastinne, Mary B. Callanan, Steven Le Gouill

Blood (2024) 144 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2024-206778

Published: 2024

Journal Articles

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Blood (2024) 144 (Supplement 1): 748.

https://doi.org/10.1182/blood-2024-198021

Published: 2024

Journal Articles

Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Catherine S. Diefenbach, Andrew D. Zelenetz, Charles Herbaux, Monica Tani, Roch Houot, Mariana Bastos-Oreiro, Hervé Tilly, Thomas Gastinne, Catherine Thieblemont, Wilfred Leung, Katerina Hatzi, Murali Kesavan, Simona Barlera, Michelle Boyer, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 577.

https://doi.org/10.1182/blood-2024-198624

Published: 2024

Journal Articles

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Marion Aymard, Morgane Cheminant, Roch Houot, Anne Cuozzo, Elodie Gat, Catherine Thieblemont, Laure Ricard, Louise Roulin, Krimo Bouabdallah, Violaine Safar, Stephanie Guidez, Amandine Fayard, Gabriel Brisou, Loic Ysebaert, Olivier Hermine, Benoit Tessoulin, Charles Herbaux, Steven Le Gouill, Clementine Sarkozy

Blood (2024) 144 (Supplement 1): 239.

https://doi.org/10.1182/blood-2024-198920

Published: 2024

Journal Articles

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Blood (2024) 144 (Supplement 1): 469.

https://doi.org/10.1182/blood-2024-197938

Published: 2024

Journal Articles

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Blood (2024) 144 (Supplement 1): 4479.

https://doi.org/10.1182/blood-2024-193960

Published: 2024

Journal Articles

Efficacy of Chemo-Free Combination Therapy with BRAF Inhibitor and Rituximab in Classic Hairy Cell Leukemia: Insights from the French Experience

Luca Inchiappa, Lise Willems, Jérôme Paillassa, Charles Herbaux, Cecile Tomowiak, Anne Lok, Diane Lara, Bijou Fontanet, Urbain Tauveron-Jalenques, Antoine Ittel, Adrien Caillet, Norbert Vey, Xavier Troussard

Blood (2023) 142 (Supplement 1): 6170.

https://doi.org/10.1182/blood-2023-186971

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CD47-blockade induces programmed necroptosis and complements the effects of BCL-2 inhibition in lymphoid malignancies

Epitranscriptomic signatures define prognosis and therapeutic vulnerabilities in large B-cell lymphoma

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group

Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy

Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa

Multi-omics integration reveals therapeutic vulnerabilities and immune microenvironment subtypes in Acute Myeloid Leukemia

N6-methyladenosine (m6A) RNA modification is required to final plasma cell differentiation

Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

CRISPR-ko screen identifies RARα inhibition as a strategy to increase CD38 expression in multiple myeloma and potentiate anti-CD38 therapy.

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Efficacy of Chemo-Free Combination Therapy with BRAF Inhibitor and Rituximab in Classic Hairy Cell Leukemia: Insights from the French Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only